We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNVA
301
DELISTED
Rennova Health, Inc.
RNVA
$41K ﹤0.01%
67
-138
-67% -$239K
IMNN icon
302
Imunon
IMNN
$6.43M
$36K ﹤0.01%
7
-21
-75% -$108K
IPCI
303
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$33K ﹤0.01%
17
-2
-11% -$39
ACER
304
DELISTED
Acer Therapeutics Inc
ACER
$10K ﹤0.01%
+9,530
New +$315K
ALBO
305
PUT
DELISTED
Albireo Pharma Inc
ALBO
$6K ﹤0.01%
6
– –
PRSN
306
DELISTED
PERSEON CORP COM STK NEW (DE)
PRSN
$4K ﹤0.01%
16,451
-553,534
-97% -$283K
ADAP
307
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-10,004
Closed -$120K
ADVM
308
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-53
Closed -$437K
ADVM
309
PUT
DELISTED
Adverum Biotechnologies
ADVM
– –
-30
Closed -$247K
AGIO icon
310
CALL
Agios Pharmaceuticals
AGIO
$2.11B
– –
-233
Closed -$1.65M
AGIO icon
311
Agios Pharmaceuticals
AGIO
$2.11B
– –
-109,521
Closed -$7.73M
AGIO icon
312
PUT
Agios Pharmaceuticals
AGIO
$2.11B
– –
-1,173
Closed -$8.28M
ALNY icon
313
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-1,676
Closed -$13.5M
ALNY icon
314
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-6,809
Closed -$547K
ALNY icon
315
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-789
Closed -$6.34M
ASRT
316
DELISTED
Assertio
ASRT
– –
-833
Closed -$937K
ATNM icon
317
Actinium Pharmaceuticals
ATNM
$27.7M
– –
-2,281
Closed -$121K
BHC icon
318
Bausch Health
BHC
$1.68B
– –
-1,171
Closed -$209K
BHC icon
319
PUT
Bausch Health
BHC
$1.68B
– –
-16
Closed -$285K
BIIB icon
320
Biogen
BIIB
$31.9B
– –
-78,629
Closed -$22.6M
BPMC
321
DELISTED
Blueprint Medicines
BPMC
– –
-308,504
Closed -$6.95M
CASI
322
DELISTED
CASI Pharmaceuticals
CASI
– –
-20,254
Closed -$217K
CDTX
323
DELISTED
Cidara Therapeutics
CDTX
– –
-15,302
Closed -$3.89M
CYH icon
324
Community Health Systems
CYH
$393M
– –
-52,510
Closed -$1.86M
CYH icon
325
PUT
Community Health Systems
CYH
$393M
– –
-801
Closed -$2.83M
11 12
13
14 15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.